| Literature DB >> 32411430 |
Chunhong Liu1,2, Jian Ji1, Zhujian Wang1, Huiwen Chen1, Wenjun Cao1,2, Xinghuai Sun2.
Abstract
PURPOSE: The objective of this study was to evaluate the microbiological spectrum and antibiotic susceptibilities of isolates in posttraumatic endophthalmitis over a 15-year period.Entities:
Year: 2020 PMID: 32411430 PMCID: PMC7210529 DOI: 10.1155/2020/5053923
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Microbiological spectrum of isolated organisms from 2004 to 2019.
| Organisms |
| Total (%) |
|---|---|---|
| Gram positive | 848 | 84.5 |
| | 303 | 30.2 |
| | 113 | 11.3 |
| Other | 259 | 25.8 |
| | 36 | 3.6 |
| | 27 | 2.7 |
| | 97 | 9.7 |
| Other Gram-positive bacteria | 13 | 1.3 |
| Gram negative | 109 | 10.9 |
| | 51 | 5.1 |
| Gram-negative | 23 | 2.3 |
| Gram-negative bacteria # | 35 | 3.5 |
| Fungi | 46 | 4.6 |
| Total | 1003 | 100 |
& refres to alpha hemolytic streptococcus and beta hemolytic streptococcus^ Bacillus cereus and Bacillus subtilis K. pneumoniae, E. coli, Serratia sp., Enterobacter agglomerans, Proteus sp., and Enterobacter sp. Acinetobacter sp., Haemophilus sp., Moraxella sp., and Neisseria sp. #Flavobacterium breve, Pseudomonas maltophilia, Vibrio flurialis, Flavobacterium indologenes, Pseudomonas stutzeri, Pseudomonas oryzihabitans, and Pseudomonas aeruginosa
Figure 1Time trends of different isolated organisms from 2004 to 2019. 1, July 2004 to June 2007; 2, July 2007 to June 2010; 3, July 2010 to June 2013; 4, July 2013 to June 2016; 5, July 2016 to July 2019.
Antibiotic susceptibilities of Gram-positive organisms from 2004 to 2019.
| Antibiotic | Number of susceptible/total number tested | Percent susceptible |
|---|---|---|
| Vancomycin | 775/778 | 99.6 |
| Penicillins/beta lactams | ||
| Penicillin G | 256/735 | 34.8 |
| Methicillin/oxacillin | 268/680 | 39.4 |
| Fluoroquinolones | ||
| Ciprofloxacin | 493/763 | 64.7 |
| Ofloxacin | 364/466 | 78.1 |
| Levofloxacin | 469/570 | 82.3 |
| Moxifloxacin | 140/154 | 90.9 |
| Others | ||
| Erythromycin | 243/740 | 32.8 |
| Chloramphenicol | 478/613 | 78.0 |
| TMP-SMX | 248/411 | 60.3 |
| Tobramycin | 255/381 | 66.9 |
Antibiotic susceptibilities of Gram-negative organisms from 2004 to 2019.
| Antibiotic | Number of susceptible/total number tested | Percent susceptible |
|---|---|---|
| Penicillins/beta lactams | ||
| Ampicillin | 19/58 | 32.8 |
| Cephems | ||
| Cefuroxime | 26/36 | 72.2 |
| Ceftriaxone | 54/79 | 68.4 |
| Ceftazidime | 72/91 | 79.1 |
| Aminoglycosides | ||
| Gentamicin | 89/93 | 95.7 |
| Tobramycin | 69/76 | 90.8 |
| Amikacin | 87/92 | 94.6 |
| Fluoroquinolones | ||
| Ciprofloxacin | 86/92 | 93.5 |
| Levofloxacin | 68/71 | 95.8 |
| Others | ||
| Imipenem | 64/72 | 88.9 |
| Meropenem | 45/47 | 95.7 |
| Ertapenem | 24/30 | 80.0 |
| TMP-SMX | 64/73 | 87.7 |
Figure 2Time trends of bacterial susceptibilities. 1, July 2004 to June 2007; 2, July 2007 to June 2010; 3, July 2010 to June 2013; 4, July 2013 to June 2016; 5, July 2016 to July 2019. Susceptibility testing was unavailable for levofloxacin from July 2004 to July 2007. (a) Ciprofloxacin. (b) Levofloxacin. (c) Tobramycin. (d) TMP-SMX.
Antibiotic susceptibilities trends for organisms from 2004 to 2019.
|
| Overall bacteria | Gram-positive bacteria | Gram-negative bacteria |
|---|---|---|---|
| Ciprofloxacin | <0.001 | <0.001 | 0.943 |
| Levofloxacin | 0.005 | 0.004 | 0.726 |
| Tobramycin | 0.629 | 0.173 | 0.767 |
| TMP-SMX | <0.001 | <0.001 | 0.416 |
| Chloramphenicol | / | 0.001 | / |
| Ceftazidime | / | / | 0.003 |
χ2 test for trend. Underlined values mean statistically significant at P < 0.05.